Semaglutide provides a potential therapeutic avenue for aging-related neurodegenerative diseases, such as Alzheimer's disease through enhanced brain glucose metabolism.
The comparable safety data presented by Novo Nordisk strengthens Semaglutide’s profile as a potential candidate in the early Alzheimer’s Disease market and provides the much-needed impetus as a treatment to slow the disease progression.
According to studies, having diabetes at the age of 55 increases the likelihood of acquiring dementia and Alzheimer's disease due to an increased risk of brain artery damage. Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist, mimics the natural...
